FAQ on Ulipristal Acetate as a Potential New Regimen for Medication Abortion

In January 2025, the New England Journal of Medicine Evidence published the results from a proof-of-concept study establishing the potential of ulipristal acetate in a combined regimen with misoprostol for medication abortion. The findings justify further investigation.

We have compiled a list of Frequently Asked Questions to provide quick and accessible answers to common queries about our early-stage research into ulipristal acetate for this new purpose.

Este FAQ (preguntas frecuentes) también está disponible en español.